Back to top

Why PDL BioPharma (PDLI) Could Be Positioned for a Surge
August 28, 2017

Read MoreHide Full Article

PDL BioPharma, Inc. (PDLI - Free Report) is an acquirer and manager of products, royalty agreements, and debt facilities that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PDLI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that PDLI International could be a solid choice for investors.

Current Quarter Estimates for PDLI

In the past 30 days, one estimate has gone higher for PDL BioPharma while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 5 cents a share 30 days ago, to 13 cents a share today, a move of 160%.

Current Year Estimates for PDLI

Meanwhile, PDL BioPharma’scurrent year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 19 cents per share 30 days ago to 69 cents per share today, an increase of 263.2%.

PDL BioPharma, Inc. Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 14.2% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (String Buy) stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


PDL BioPharma, Inc. (PDLI) - free report >>


More from Zacks Tale of the Tape

You May Like